Valion Bio, Inc. Common Stock (NASDAQ:VBIO) Short Interest Update

Posted by Patrick Bannon on Sep 12th, 2026

Valion Bio, Inc. Common Stock (NASDAQ:VBIO – Get Free Report) saw a significant decline in short interest in the month of August. As of August 31st, there was short interest totaling 340,186 shares, a decline of 79.3% from the August 15th total of 1,646,299 shares. Based on an average trading volume of 786,030 shares, the days-to-cover ratio is presently 0.4 days. Currently, 39.3% of the shares of the company are sold short.

Analyst Ratings Changes

A number of research firms recently weighed in on VBIO. Wall Street Zen raised shares of Valion Bio, Inc. Common Stock to a “hold” rating in a report on Saturday, September 5th. Weiss Ratings reissued a “sell (e+)” rating on shares of Valion Bio, Inc. Common Stock in a research note on Friday, July 17th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has an average rating of “Sell”.

Read Our Latest Analysis on Valion Bio, Inc. Common Stock

Valion Bio, Inc. Common Stock Stock Up 2.7%

VBIO opened at $2.26 on Friday. The stock’s 50 day moving average price is $6.58 and its 200 day moving average price is $16.38. The company has a debt-to-equity ratio of 1.74, a current ratio of 1.11 and a quick ratio of 0.86. The stock has a market cap of $2.01 million, a P/E ratio of -0.01 and a beta of 1.79. Valion Bio, Inc. Common Stock has a 12 month low of $2.16 and a 12 month high of $80.19.

About Valion Bio, Inc. Common Stock

(Get Free Report)

Tivic Health Systems is a commercial-stage medical technology company that develops and markets non-drug, neuromodulation-based therapies for nasal and sinus health. The company’s solutions are designed to alleviate sinus pain, pressure and congestion through gentle microcurrent and vibration stimulation. By targeting the underlying nerve pathways in the nasal passages, Tivic Health aims to provide an alternative to over-the-counter and prescription medications without introducing systemic side effects.

The flagship product, ClearUP™ Sinus Pain Relief, is an FDA-cleared, hand-held device intended for home use.